# Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

> **NCT01284634** · PHASE2 · COMPLETED · sponsor: **GW Research Ltd** · enrollment: 25 (actual)

## Conditions studied

- Fatty Liver

## Interventions

- **DRUG:** GWP42003 200 mg/day Dose
- **DRUG:** GWP42003 400 mg/day Dose
- **DRUG:** GWP42003 800 mg/day Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01284634
- **Lead sponsor:** GW Research Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-03
- **Primary completion:** 2012-07-13
- **Final completion:** 2012-07-13
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284634, "Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01284634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*